1. |
Worldwide malaria control efforts must be resurrected |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Eptacog-α warranted for haemophilia in the UK |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
ESRD costs and burden reduced with losartan in the EU |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 5-6
Kimberley Salmon,
Preview
|
|
摘要:
In the European Union (EU), an estimated 17.1 million individuals have diabetes mellitus, with type 2 diabetes accounting for 95% of this burden. Across most of industrialised Europe, type 2 diabetes is the most prominent cause of end-stage renal disease (ESRD), a condition which consumes a significant proportion of many national healthcare system budgets. In addition, the current serious shortage of staff at dialysis centres contributes to the burden on healthcare systems. Consequently, treatments which may reduce the incidence of ESRD and the associated costs are receiving much attention from healthcare professionals. One such treatment is losartan, a potent and specific non-peptide angiotensin II receptor antagonist with renal protective effects due to its action on the renin-angiotensin system, which is thought to play a role in renal failure. A study investigating the potential effect of losartan therapy on the burden of ESRD in the EU was presented at a poster session at the European Society of Cardiology Congress
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Gastric inhibitory polypeptide analogues: antidiabetic potential |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Inhaled insulin: benefits in types 1 and 2 diabetes |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 9-11
Alison Taylor,
Raewyn Poole,
Preview
|
|
摘要:
'Exubera', an inhaled dry-powder insulin, is effective in the treatment of type 1 and type 2 diabetes mellitus, according to results from phase III studies presented at the 38th Annual Meeting of the European Association for the Study of Diabetes (EASD) [Budapest, Hungary; August-September 2002]. 'Exubera' was at least as effective as conventional SC insulin therapy in the treatment of type 1 and type 2 diabetes, and provided improved glycaemic control in patients with type 2 diabetes who had an insufficient response to oral antihyperglycaemic agents. An analysis of patients enrolled in phase II studies, showed that the level of satisfaction was greater in patients treated with 'Exubera', compared with those receiving conventional insulin therapy.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Gabexate ± octreotide for HIV-associated pancreatic disorders |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1362,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|